| abstract |
] nThe present invention provides a pharmaceutical ncomposition for prevention or treatment of osteoarthritis nincluding cells or cell groups having a specific size or n5 less, a kit for preparing a cell therapeutic agent, and a nmethod for manufacturing a therapeutic agent for nosteoarthritis. Mixed cells, which are selected to a nspecific size or less as an active ingredient of the npresent invention, of transformed mammalian cells with n10 TGF-P and untransformed mammalian cells minimize naggregation between chondrocytes and have beneficial ntherapeutic effects. In addition, when administering the nselected mixed cells having the specific size or less to a npatient, patient compliance may be improved, and it is easy n15 to manage quality in therapeutic agent manufacturing nfacilities or hospitals. n37 |